Novartis and Roche have collaborated with Oxford researchers at the Big Data Institute to develop an artificial intelligence (AI) model aimed at reclassifying the progression of multiple sclerosis (MS). This effort utilized the largest collection of clinical trial data, known as the Novartis-Oxford MS dataset, which includes information from over 8,000 people living with MS. The dataset was built over more than a decade, compiling data from over 40 studies, 35,000 patients, and 200,000 MRIs. The AI-driven research, published in Nature Medicine, followed patients for up to 15 years and suggests that MS is likely a single disease characterized by a gradual shift in disease progression. Additionally, a new AI consortium named C-brAIn has been launched to develop an 'AI biomedical scientist' to accelerate research in Alzheimer's disease.